Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q3 2019 · 10-Q
Revenue$42.62M$42.62M+115.4% vs Q3 2018 Net Income-$33.60M-$33.60MN/M vs Q3 2018 EPS Diluted-$0.42-$0.42N/M vs Q3 2018 Gross Profit$25,429,000+108.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$25,471,000N/M Free Cash Flowderived-$24,423,000N/M Margins · derivedGross margin59.7%−2.1 pt vs Q3 2018
Operating margin-81.8%+129.4 pt vs Q3 2018
Net margin-78.8%+115.0 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 12, 2019 · 43 d after period end